Journal
CURRENT MOLECULAR PHARMACOLOGY
Volume 15, Issue 5, Pages 763-778Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1874467214666210920104352
Keywords
Soluble epoxide hydrolase; arachidonic acid; metabolic syndrome; hypertension; diabetes; clinical; cardiovascular
Ask authors/readers for more resources
This article discusses the importance of Epoxide hydrolase (EH) as a crucial enzyme for catabolism, detoxification, and regulation of signaling molecules, and highlights the potential applications of sEH as a pharmacological target in various diseases. Specifically, it focuses on the development and clinical application of soluble epoxide hydrolase inhibitors (sEHIs) for the management of metabolic syndrome and related disorders.
Epoxide hydrolase (EH) is a crucial enzyme responsible for catabolism, detoxification, and regulation of signaling molecules in various organisms including human beings. In mammals, EHs are classified according to their DNA sequence, sub-cellular location, and activity into eight major classes: soluble EH (sEH), microsomal EH (mEH), leukotriene A4 hydrolase (LTA4H), cholesterol EH (ChEH), hepoxilin EH, paternally expressed gene 1 (peg1/MEST), EH3, and EH4. The sEH, an alpha/beta-hydrolase fold family enzyme, is an emerging pharmacological target in multiple diseases namely, cardiovascular disease, neurodegenerative disease, chronic pain, fibrosis, diabetes, pulmonary diseases, and immunological disease. It exhibits prominent physiological effects including anti-inflammatory, anti-migratory, and vasodilatory effects. Its efficacy has been documented in various clinical trials and observational studies. This review specifically highlights the development of soluble epoxide hydrolase inhibitors (sEHIs) in the clinical setting for the management of metabolic syndrome and related disorders, such as cardiovascular effects, endothelial dysfunction, arterial disease, hypertension, diabetes, obesity, heart failure, and dyslipidemia. In addition, limitations and future aspects of sEHIs have also been highlighted which will help the investigators to bring the sEHI to the clinics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available